iTeos Therapeutics regains rights to IDO1 inhibitor

Belgium-based iTeos Therapeutics SA has regained rights to an early-stage cancer drug from Pfizer Inc which was being investigated in a Phase 1 trial as a potential single agent for treating patients with malignant gliomas.

Full text available to subscribers only. Click here for information on subscribing to MedNous.